Would think so psych, given the low tox of PTX200 at current levels in all data, I see no reason why the FDA would unnecessilary delay recruitment for the AML trial given the urgent need for additional therapies. Possibly slight change to protocols will be required but would think won't be too far off getting underway once again.
